CD274 and non-small cell lung carcinoma: Moreover, the efficacy of combination therapy extends across diverse patient groups, showing promising results for squamous and non-squamous NSCLC patients and across all PD-L1 expression levels, including high, negative, and intermediate PD-L1 (1% ≤ PD-L1 < 50%) groups [57].